Streetbeat News

Stock Prices

GTHX

G1 Therapeutics shares are trading lower after the company's PRESERVE 2 Phase 3 trial of Trilaciclib did not achieve statistical significance in the primary endpoint of overall survival.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:18 am

RGLS

Regulus Therapeutics Inc. (NASDAQ:RGLS) announced positive topline results from the third cohort of its Phase 1b study of RGLS8429 for ADPKD treatment. The study showed that RGLS8429 was well tolerated and demonstrated a dose response in reducing disease severity markers. Enrollment for the fourth cohort has begun, and the company plans to discuss a potentially pivotal Phase 2/3 study with the FDA.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:10 am

COIN

HOOD

MARA

MSTR

RIOT

The anticipated approval of spot Ethereum ETFs could lead to a significant drop in Ether's price, with potential impacts on various crypto-related stocks. Analysts are divided on the potential benefits and consequences of the ETF launch.

Portfolio Pulse from Benzinga Neuro

June 24, 2024 | 11:08 am

ONCY

Oncolytics Biotech Inc. (NASDAQ:ONCY) announced that CEO Dr. Matt Coffey will take a medical leave of absence, with Wayne Pisano, Chair of the Board, stepping in as interim CEO. Pisano has extensive experience in the pharmaceutical and biotech industries, including leadership roles at Sanofi Pasteur and VaxInnate.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:08 am

HRMY

Harmony Biosciences has received FDA approval for a supplemental new drug application for WAKIX, which is expected to enhance its market position and potentially increase revenues.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:05 am

AXGN

Axogen, Inc. (NASDAQ:AXGN) has launched a new product, Avive+ Soft Tissue Matrix, designed to aid in nerve healing. This product is a resorbable, multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during the critical phase of peripheral nerve healing. The product complies with FDA regulations and aims to address a significant need in the $800 million nerve protection market.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:03 am

ALNY

Alnylam Pharmaceuticals announced positive topline results from its HELIOS-B Phase 3 study of Vutrisiran. The study achieved statistical significance on both primary and all secondary endpoints.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:02 am

EFTR

eFFECTOR Therapeutics has announced plans to wind down its operations and seek potential strategic alternatives. The company also expects to delist from Nasdaq.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:01 am

ALNY

Trading in ALNY was halted at 6:55:00 a.m. ET pending news. Investors should stay tuned for updates as the halt indicates significant news is forthcoming.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 10:55 am

BA

ITA

PPA

Boeing Co (NYSE:BA) risks potential criminal charges as U.S. prosecutors reportedly recommend legal action against the company for allegedly breaching a 2021 deferred prosecution agreement following two fatal 737 MAX crashes. The Justice Department has until July 7 to decide on prosecuting Boeing, which could result in significant penalties. Boeing has denied any wrongdoing, but discussions with the Justice Department are ongoing. The stock has lost more than 14% in the last 12 months. Investors can gain exposure to Boeing via IShares U.S. Aerospace & Defense ETF (BATS:ITA) and Invesco Aerospace & Defense ETF (NYSE:PPA).

Portfolio Pulse from Shivani Kumaresan

June 24, 2024 | 10:47 am